Оникиенко Сергей Б. (RU),Ниворожкин Алекс (US),Земляной Александр В. (RU)
申请号：
RU2014102752/15
公开号：
RU2014102752A
申请日:
2012.06.28
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A preparation containing heat shock protein-70 (HSP70) and a pharmaceutically acceptable carrier. The drug according to claim 1, containing a therapeutically effective amount of HSP70.3. The drug according to claim 1, intended for intravenous, subcutaneous, intranasal, oral or inhaled administration. The drug according to claim 2, intended for intravenous, subcutaneous, intranasal, oral or inhaled administration. The drug according to claim 1, where HSP70 is a recombinant human HSP70.6. The preparation according to claim 2, wherein HSP70 is a recombinant human HSP70.7. The preparation according to claim 3, wherein HSP70 is a recombinant human HSP70.8. The preparation according to claim 4, wherein HSP70 is a recombinant human HSP70.9. The preparation according to claim 1, wherein HSP70 is a pegylated HSP70.10. The drug according to claim 2, where HSP70 is a pegylated HSP70.11. The drug according to claim 3, where HSP70 is a pegylated HSP70.12. The drug according to claim 4, where HSP70 is a pegylated HSP70.13. The drug according to any one of paragraphs. 1-12, containing HSP 70 in an amount of 0.1 to 10 mg. 14. A method for treating HSP70-dependent disorders or conditions, comprising administering to the subject HSP70 in a therapeutically effective amount, providing treatment for HSP-dependent disorders or conditions. A method of improving performance, reducing the severity of chronic fatigue syndrome, reducing muscle damage or muscle degeneration, including the introduction of a HSP70 to a mammal in a therapeutically effective amount, providing increased performance, reducing the severity of chronic fatigue syndrome, reducing damage to mice1. Препарат, содержащий белок теплового шока-70 (БТШ70) и фармацевтически приемлемый носитель.2. Препарат по п. 1, содержащий терапевтически эффективное количество БТШ70.3. Препарат по п. 1, предназначенный для внутривенного, подкожного, интраназального, перорального или ингаляционного введения.4. Препарат по п. 2, предназначен
